業績

2017年

• Uchida H, Hamada H, Nakano K, Kwon H, Tahara H, Cohen JB, Glorioso JC. Oncolytic herpes simplex virus vectors fully retargeted to tumor-associated antigens. Current Cancer Drug Targets. In press.
• Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y. (2017) Chimeric anti-human podoplanin antibody NZ-12 of lambda light chain exerts higher antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity compared with NZ-8 of kappa light chain. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 36:25-29.
• Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK. (2017) Antiglycopeptide mouse monoclonal antibody LpMab-21 exerts antitumor activity against human podoplanin through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 36:20-24.

 
2016年

• Okubo Y, Uchida H*, Wakata A, Suzuki T, Shibata T, Ikeda H, Yamaguchi M, Cohen JB, Glorioso JC, Tagaya M, Hamada H, Tahara H. (2016) Syncytial mutations do not impair the specificity of entry and spread of a glycoprotein D receptor-retargeted herpes simplex virus. Journal of Virology. 90:11096-11105. *Corresponding author.
• Ma Z, Li W, Yoshiya S, Xu Y, Hata M, Eldaravish Y, Markova T, Yamanishi K, Yamanishi H, Tahara H, Tanaka Y, and Okamura H. Augmentation of immune checkpoint blockade therapy with IL-18. Clin Cancer Res. 2016 Jun 15;22(12):2969-80. doi: 10.1158/1078-0432.CCR-15-1655. （査読有）
• Shibata T, Uchida H, Shiroyama T, Okubo Y, Suzuki T, Ikeda H, Yamaguchi M, Miyagawa Y, Fukuhara T, Cohen JB, Glorioso JC, Watabe T, Hamada H, Tahara H. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. Gene Ther. 2016 Jun;23(6):479-88. doi: 10.1038/gt.2016.17. （査読有）
• Tanaka K, Miyata H, Sugimura K, Kanemura T, Mizote Y, Hamada-Uematsu M, Yamasaki, M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, and Tahara H. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Science. 2016 Jun;107(6):726-33. doi: 10.1111/cas.12938. （査読有）
• Kimura Y, Nagai N, Tsunekawa N, Sato-Matsushita M, Yoshimoto T, Cua DJ, Iwakura Y, Yagita H, Okada F, Tahara H, Saiki I, Irimura T, Hayakawa Y. IL-17A-producing CD30+ Vδ1 T cells drive inflammation-induced cancer progression. Cancer Sci. 2016 Jul 6. doi: 10.1111/cas.13005. [Epub ahead of print] （査読有）

 
2015年

• Tahara H, Jinushi M. Anti-cancer drug U.S. Serial number: 12/995,942 (MFG-E8を抗がん剤として用いる特許) 【米国特許認可】 2015年10月7日

 
2013年

• Jinushi M, Yagita H, Yoshiyama H, Tahara H. Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells. Trends Mol Med. 19(9):536-45. 2013.（査読有）
• Tanaka K, Miyashiro I, Yano M, Kishi K, Motoori M, Shingai T, Noura S, Ohue M, Ohigashi H, Ishikawa O. Visceral fat changes after distal gastrectomy according to type of reconstruction procedure for gastric cancer. Jinushi M, Yagita H, Yoshiyama H, Tahara H. Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells. Trends Mol Med. 19(9):536-45. 2013.（査読有）

 
2012

• Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, Tahara H,　Inoue N, and Seya T.TLR3/TICAM-1 signaling converts tumor-supporting myeloid cells to tumoricidal Effectors. Proc Natl Acad Sci U S A， 109(6):2066-71. 2012.（査読有）

 
2011年

• Hayakawa Y, Sato M, Takeda K, Iwakura Y, Tahara H, Irimura T. Early activation and IFN-γ production of tumor infiltrating mature CD27high NK cells, Cancer Science 102(11):1967-71 2011.
• Hikichi M, Kidokoro M, Haraguchi T, Iba H, Shida H, Tahara H & Nakamura T. MicroRNA regulation of vaccinia virus for enhanced oncolytic activity and reduced pathogenicity in oncolytic virotherapy. Molecular Therapy 19:1107-15, 2011（査読有）
• Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, Tahara H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A. 108:12425-30. 2011（査読有）
• Yamano T, Watanabe S, Hasegawa H, Suzuki T, Abe R, Tahara H, Nitta T, Ishimaru N, Sprent J, and Kishimoto H. Ex-vivo expanded DC induce donor-specific central and peripheral tolerance and prolong the acceptance of donor skin allografts. Blood 117:2640-2648, 2011
• Kenji Nakano, Masatoshi Kobayashi, Kei-ichiro Nakamura,Takeshi Nakanishi,Ryutaro Asano, Izumi Kumagai,Hideaki Tahara,Michihiko Kuwano,Justus B. Cohen,and Joseph C. Glorioso. Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor. Virology 413:2–18, 2011.（査読有）

 
2010年以前

• Baba T, Sato-Matsushita M, Kanamoto A, Itoh A, Oyaizu N, Inoue Y, Kawakami Y, Tahara H. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402 J Translational Medicine 8:84-96, 2010
• Jinushi M, Sato M, Kanamoto A, Itoh A, Nagai S, Koyasu S, Dranoff G, and Tahara H. Milk Fat Globule EGF-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. J Exp. Med. 206:1317-1326, 2009.（査読有）
• Suzuki T, Ogawa S, Tanabe K, Tahara H, Abe R,Kishimoto H. Induction of anti-tumor immune response by homeostatic proliferation and CD28 signaling. J Immunol 180: 4596–4605, 2008
• Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, and Tahara H. Systemic Administration of IL-23 Induces Potent Anti-tumor Immunity Primarily Mediated through Th1-type Response in Association with the Endogenously Expressed IL-12. J Immunol 178:7571-80, 2007
• Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for anti-angiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2 (VEGFR2). Cancer Research, 65: 4939-4946, 2005.
• Tani K, Azuma M, Nakazaki Y, Oyaizu N, Hase H, Ohata J, Takahashi K, OiwaMonna M, Hanazawa K, Wakumoto Y, Kawai K, Noguchi M, Soda Y, Kunisaki R, Watari K, Takahashi S, Machida U, Satoh N, Tojo A, Maekawa T, Eriguchi M, Tomikawa S, Tahara H, Inoue Y, Yoshikawa H, Yamada Y, Iwamoto A, Hamada H, Yamashita N, Okumura K, Kakizoe T, Akaza H, Fujime M, Clift S, Ando D, Mulligan R, Asano S. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther. 10:799-816, 2004.
• Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H, Hamada H. (2004) Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Molecular Therapy. 10:162-171. (査読有)
• Oikawa Y, Shimada A, Kasuga A, Morimoto J, Osaki T, Tahara H, Miyazaki T, Tashiro F, Yamato E, Miyazaki J, Saruta T. Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol. 171:5865-75, 2003
• Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Research 63:4112-8, 2003
• Numasaki M, Fukushi JI, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT.Interleukin-17 promotes angiogenesis and tumor growth. Blood 101; 2620-2627, 2003.
• Qin, L, Ding, Y, Tahara H, and Bromberg, JS. Viral IL-10-Induced Immunosuppression Requires Th2 Cytokines and Impairs APC Function Within the Allograft. J Immunol 166: 2385-2393, 2001
• Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer Res 60:4838-44, 2000.
• Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Robbins PD, Lotze MT, Tahara H. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 60: 2209-17,2000.
• Nishioka, Y., Robbins, P.D., Lotze, M.T., and Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59:4035-41, 1999.
• Hashimoto, W, Osaki, T, Okamura, H, Robbins, P.D., Kurimoto, M, Nagata S., Lotze, M.T., Tahara H. Differential antitumor effects of administration of rIL-18 or rIL-12 are mediated primarily by Fas-FasL and perforin induced tumor apoptosis respectively. J Immunol 163:583-9, 1999
• Osaki, T., P ron, J-M., Cai, Q., Okamura, H., Robbins, P.D., Kurimoto, M., Lotze, M.T., and Tahara H. IFN--inducing factor/IL-18 Administration Mediates IFN- and IL-12 Independent Anti-tumor Effects. J. Immunol. 160:1742-1749, 1998
• Atkins, B.A., Robertson, M.J., Gordon, M., Lotze, M.T., DeCoste, M., DuBois, J.S., Ritz, J., Sandler, A.B., Edington, H.D., Garzone, P.D., Mier, J.W., Canning, C.M., Battiato, L., Tahara H., and Sherman, M.L. Phase I evaluation of intravenous recombinant human interleukin-12 (rhIL-12) in patients with advanced malignancies. Clin. Cancer Res. 3: 409-417, 1997.
• Berman, R.M., Suzuki, T., Tahara H., Robbins, P.D., Narula, S.K.,and Lotze, M.T.Systemic administration of cellular IL-10 induces and effective, specific, and long-lived immune response against established tumors in mice. J. Immunol. 157:231-238, 1996.
• Zitvogel, L., Robbins, P.D., storkus, W.J., Clarke, M.R., Maeurer, M.J., Campbell, R.L., Davis, C.G., Tahara H., Schreiber, R.D., and Lotze, M.T. B7.1 costimulation markedly enhances IL-12-mediated antitumor immunity in vivo. E. J. immunol. 26:1335-1341, 1996.
• Qin, L. Chavin K.D., Ding, Y., Tahara H., Favaro, J., Woodward, J., Suzuki, T., Robbins, P.D., Lotze, M.T., Bromberg, J.S., Retrovirus-mediated transfer of viral interleukin-10 gene prolongs murine cardiac allograft survival. J. Immunol. 156:2316-2323, 1996.
• Tahara H. and Lotze, M.T. IL-12 Gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Human Gene Therapy 6:1607-1624, 1995.
• Zitvogel, L., Tahara H., Robbins, P.D., Storkus, W.J., Clarke, M.R., Nalesnik, M.A., and Lotze, M.T. Cancer Immunotherapy of established tumors with interleukin-12: Effective delivery by genetically engineered fibroblasts. J. Immunol.155:1393-1403, 1995.
• Suzuki, T., Tahara H., Narula, S., Moore, K.W., Robbins, P.D., and Lotze, M.T. Viral interleukin 10 (vIL-10), the human herpes virus-4 cellular IL-10 (cIL-10) homologue, induces local anergy to allogeneic and syngeneic tumors. J. Ex. Med. 182:477-486, 1995.
• Tahara H., Zitvogel, L., Storkus, W.J., Zeh, H.J.III, McKinney, T.G., Schreiber, R.D., Gubler, U., Robbins, P.D., Lotze, M.T. Effective eradication of established murine tumors with interleukin 12 (IL-12) gene therapy using a polycistronic retroviral vector. J. Immunol. 154: 6466-6474, 1995.
• Zitvogel, L., Tahara H., Cai Q., Storkus, W.J., Muller G., Wolf, S.F., Gately, M.K., Robbins, P.D., and Lotze, M.T. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Human Gene Therapy 5: 1493-1506, 1994.
• Nastala, L., Edington, H.D., McKinney, T.G., Tahara H., Nalesnik, M., Brunda, M.J., Gately M.K., Wolf, S.F., Schreiber, R.D., Stewart T., Storkus, W.J., and Lotze, M.T. Recombinant interleukin-12 (IL-12) administration induces tumor regression in assciation with interferon-gamma production. J. Immunol. 153: 1697-1706, 1994
• Tahara H., Zeh, H.J. III, Storkus, W.J., Pappo, I., Watkins, S.C., Gubler, U., Wolf, S.F., Robbins, P.D., Lotze, M.T. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce anti-tumor immunity to a murine melanoma in vivo. Cancer Research 54: 182-189, 1994
• Doki, Y., Shiozaki, H., Tahara H., Inoue, M., Oka H., Iihara, K., Kadowaki T., Takeichi, M., Mori, T. Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Research 53; 3421-3426, 1993.
• Shiozaki H., Tahara H., Oka H., Miyata M., Kobayashi K., Tamura S., Iihara K., Doki Y., Hirano S., Takeichi M., Mori T.: Expression of immuno-reactive E-cadherin adhesion molecules in human cancers. Am. J. Pathol. 139: 17-23, 1991.